The Amyloidosis Research Consortium is a nonprofit accelerating the development of and access to new and innovative treatments. We are driving the research that will have the greatest impact on length and quality of life for patients.
Latest news from ARC
Report from the Amyloidosis Forum’s Initial Meeting at FDA
The inaugural Amyloidosis Forum took place on November 12th, 2019 at FDA’s White Oak Campus in Silver Spring, MD. We could not have hoped for a better turnout, a more spirited and productive discussion.
ARC Developing a Disease-Specific PRO Tool for Patients with ATTR Amyloidosis
ARC is developing a patient-reported outcome (PRO) measurement tool in ATTR amyloidosis to be used to understand and measure the impact of the disease on patients from the patient’s perspective.